This yielded consistent results with our prior findings, including increased activation and cell cycle cGEPs in CRC nonresponders (for example, P < 1 × 10−6 for OX40/EBI3, CellCycle-Late-S and ASA; Fig. 6g and Supplementary Fig. 10c,d). This evidence concerns the gene EBI3 and colorectal carcinoma.